The Manufacturers Life Insurance Company sells 5,046 shares of ShockWave Medical, Inc. (NASDAQ: SWAV)

The Manufacturers Life Insurance Company decreased its position in ShockWave Medical, Inc. (NASDAQ:SWAV – Get Rating) by 5.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 86,592 shares of the company’s stock after selling 5,046 shares during the period. The Manufacturers Life Insurance Company owned approx. 0.24% of ShockWave Medical worth $23,980,000 as of its most recent filing with the SEC.

→ Is this the end of capitalism? (From Porter & Company)

Several other hedge funds also recently bought and sold shares of SWAV. Barclays PLC boosted its holdings in shares of ShockWave Medical by 143.0% in the third quarter. Barclays PLC now owns 7,901 shares of the company’s stock valued at $2,198,000 after acquiring an additional 4,649 shares in the last quarter. Rockefeller Capital Management LP boosted its position in shares of ShockWave Medical by 720.5% during the third quarter. Rockefeller Capital Management LP now owns 1,001 shares of the company’s stock valued at $278,000 after acquiring an additional 879 shares in the last quarter. Los Angeles Capital Management LLC raised its holdings in shares of ShockWave Medical by 200.2% during the third quarter. Los Angeles Capital Management LLC now owns 40,289 shares of the company’s stock valued at $11,203,000 after acquiring an additional 26,869 shares during the period. MONECO Advisors LLC purchased a new stake in ShockWave Medical in the 3rd quarter valued at $226,000. Finally, Tobam ​​bought a new position in ShockWave Medical in the 3rd quarter valued at about $32,000. 90.56% of the stock is currently owned by institutional investors and hedge funds.

Wall Street analysts expect growth

A number of equities research analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft initiated coverage on ShockWave Medical in a research report on Friday, December 16th. They issued a “buy” rating and a $285.00 target price on the stock. Bank of America boosted their price target on shares of ShockWave Medical from $260.00 to $310.00 in a research report on Monday, November 7th. Morgan Stanley lowered their target price on ShockWave Medical from $290.00 to $224.00 and set an “equal weight” rating on the stock in a research report on Friday, January 6th. Finally, Wells Fargo & Company cut ShockWave Medical from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $300.00 to $235.00 in a research report on Monday, December 12th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $250.89.

ShockWave Medical trades up 3.6%

SWAV opened at $183.18 on Wednesday. The company has a quick ratio of 6.02, a current ratio of 7.29 and a debt ratio of 0.04. ShockWave Medical, Inc. has a twelve month low of $113.36 and a twelve month high of $320.54. The stock has a market cap of $6.62 billion, a price-to-earnings ratio of 78.62 and a beta of 1.04. The company has a 50 day simple moving average of $219.43 and a 200 day simple moving average of $248.47.

ShockWave Medical (NASDAQ:SWAV – Get Rating ) last posted its quarterly earnings results on Monday, November 7th. The company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.24. ShockWave Medical had a net margin of 20.48% and a return on equity of 30.08%. The company had revenue of $131.33 million for the quarter, compared to analyst estimates of $125.85 million. Analysts predict that ShockWave Medical, Inc. will post 2.94 EPS for the current fiscal year.

Insider buying and selling at ShockWave Medical

In other ShockWave Medical news, insider Isaac Zacharias sold 4,000 shares of the firm’s stock in a transaction that occurred on Friday, November 25th. The shares were sold at an average price of $261.82, for a total value of $1,047,280.00. After the sale, the insider now owns 73,021 shares in the company with a value of 19,118,358.22 dollars. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available via this link. In other ShockWave Medical news, CFO Dan Puckett sold 1,100 shares of the firm’s stock in a transaction that occurred on Friday, January 20th. The shares were sold at an average price of $177.45, for a total transaction of $195,195.00. Following the completion of the transaction, the chief financial officer now owns 39,938 shares in the company, valued at approximately $7,086,998.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Isaac Zacharias sold 4,000 shares of the company’s stock in a transaction on Friday, November 25th. The shares were sold at an average price of $261.82, for a total transaction of $1,047,280.00. Following the completion of the transaction, the insider now owns 73,021 shares in the company, valued at approximately $19,118,358.22. The information about this sale can be found here. Insiders have sold a total of 57,300 shares of company stock valued at $13,110,504 over the last 90 days. Insiders own 3.90% of the company’s shares.

ShockWave Medical Company Profile

(Get rating)

ShockWave Medical, Inc, a medical device company, is engaged in the development and commercialization of intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular and valvular heart disease worldwide. The company offers M5 catheters for the treatment of above-knee peripheral artery disease (PAD); C2 catheters for the treatment of coronary artery disease; and S4 catheters for the treatment of PAD below the knee.

Also see

Institutional Ownership by Quarter of ShockWave Medical (NASDAQ:SWAV)

This instant news alert was generated by narrative science technology and financial data from MarketBeat to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat editorial staff prior to publication. Please send questions or comments about this story to [email protected]

Before you consider ShockWave Medical, you want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and ShockWave Medical wasn’t on the list.

While ShockWave Medical currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five stocks here

13 stocks Institutional investors will not stop buying coverage
The Manufacturers Life Insurance Company sells 5,046 shares of ShockWave Medical, Inc. (NASDAQ: SWAV)

Leave a Reply

Your email address will not be published.

Scroll to top